Immunization With Bovine Herpesvirus-4-Based Vector Delivering PPRV-H Protein Protects Sheep From PPRV Challenge

Rodríguez-Martín, Daniel; Rojas, José M.; Macchi, Francesca; Franceschi, Valentina; Russo, Luca; Sevilla, Noemı́; Donofrío, Gaetano; Martı́n, Verónica

doi:10.3389/fimmu.2021.705539

Cited by 9 publications

(6 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, antigens from several viruses, such as Ebola virus, BHV-1, and PPRV were successfully expressed on BoHV-4 vector and immunization of these BoHV-4-antigens induced well neutralizing antibody responses [ 31 – 35 ]. Immunization of a recombinant vector (BoHV-4-A-PPRV-H-ΔTK) that delivers PPRV-H protein showed effective protection against PPRV infection [ 12 ]. Hence, the novel BoHV-4 strain might be used as virus vector for vaccine development.…”

Section: Discussionmentioning

confidence: 99%

Characterization and phylogenetic analysis of bovine gammaherpesvirus 4 isolated in China, 2022

et al. 2023

View full text Add to dashboard Cite

Bovine gammaherpesvirus 4 (BoHV-4) is a common virus detected in bovine with respiratory disease worldwide. In this study, we identified and characterized a novel BoHV-4 strain, referred as HB-ZJK, in vaginal swabs collected from cattle in China, 2022. The long unique region (LUR) of HB-ZJK is 10,9811 bp in length. It shares 99.17% to 99.38% nucleotide identity to five BoHV-4 strains available in GenBank and the highest similarity was seen with BoHV-4V. test (JN133502.1) strain (99.38%). Mutations, insertions or deletions were observed mainly in HB-ZJK gB (ORF8), TK (ORF21), gH (ORF22), MCP (ORF25), PK (ORF36), gM (ORF39), and gL (ORF47) genes compared to its genomic coordinates. Phylogenetic analyses of gB and TK genes showed that HB-ZJK clustered with China 512 (2019), B6010 (2009), and J4034 (2009) strains, demonstrating that the isolated HB-ZJK belongs to genotype 1. This is the first report that has revealed a comprehensive genome profile of BoHV-4 strain in China. This study will provide foundation for epidemiological investigations of BoHV-4 and contribute to the molecular and pathogenic studies of BoHV-4. Supplementary Information The online version contains supplementary material available at 10.1007/s11262-023-01981-5.

show abstract

Section: Discussionmentioning

confidence: 99%

Characterization and phylogenetic analysis of bovine gammaherpesvirus 4 isolated in China, 2022

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Recall responses to OVA were assessed by inoculating the same antigen amount three months later (3MD0), and blood samples obtained at days 7 and 30 after the second OVA inoculation (3MD7 and 3MD30). PBMCs and serum samples were obtained for analysis of the adaptive immunity induced to OVA and obtained as described in (Rojas et al, 2014b;Rodrıǵuez-Martıń et al, 2021). The sheep were housed in the Experimental Farm "La Chimenea" (IMIDRA) in excellent animal welfare conditions.…”

Section: Experimental Designmentioning

confidence: 99%

“…To characterize PBMC populations during the course of the experiment, the following antibodies were used: anti-ovine CD4 (clone 44.38), CD8 (clone 38.65), and WC1 (clone 19.19) (all from Biorad, Madrid, Spain); anti-human CD14 (clone TÜK4), CD16 (clone KD1) (both from Biorad, Madrid, Spain) and CD27 (clone LG3.A10) (Biolegend, San Diego, CA, USA); and antibovine B cell marker (clone BAQ44A) (KingFisher Biotech, Minnesota, USA) and CD62L (clone CC32) (Biorad, Madrid, Spain). Cells were labeled as described in (Rodrıǵuez- Martıń et al, 2021). To assess IFN-g production, PBMC were left unstimulated as control or stimulated with 10mg/ml OVA for 6 hours.…”

Section: Intracellular Cytokine Staining and Flow Cytometrymentioning

confidence: 99%

Adenoviral delivery of soluble ovine OX40L or CD70 costimulatory molecules improves adaptive immune responses to a model antigen in sheep

Rojas

Mancho²,

Louloudes-Lázaro

et al. 2022

Front. Cell. Infect. Microbiol.

Self Cite

View full text Add to dashboard Cite

The tumour necrosis factor superfamily OX40L and CD70 and their receptors are costimulatory signalling axes critical for adequate T and B cell activation in humans and mice. In this work we inoculated groups of sheep with human recombinant adenovirus type 5 (Ad) expressing Ovis aries (Oa)OX40L or OaCD70 or a control adenoviral vector to determine whether they could improve the immune response to the model antigen OVA. PBMCs and serum samples were obtained for analysis of the adaptive immune response to OVA at days 0, 15, 30 and 90 post-inoculation (pi). Recall responses to OVA were assessed at day 7 and 30 after the second antigen inoculation (pb) at day 90. Administration of these immunomodulatory molecules did not induce unspecific PBMC stimulation. While OaOX40L administration mainly increased TNF-α and IL-4 in PBMC at day 15 pi concomitantly with a slight increase in antibody titer and the number of IFN-γ producing cells, we detected greater effects on adaptive immunity after OaCD70 administration. AdOaCD70 inoculation improved antibody titers to OVA at days 30 and 90 pi, and increased anti-OVA-specific IgG-secreting B cell counts when compared to control. Moreover, higher IFN-γ production was detected on days 7 pi, 7 pb and 30 pb in PBMCs from this group. Phenotypic analysis of T cell activation showed an increase in effector CD8+ T cells (CD8+ CD62L- CD27-) at day 15 pi in AdOaCD70 group, concurrent with a decrease in early activated cells (CD8+ CD62L- CD27+). Moreover, recall anti-OVA CD8+ T cell responses were increased at 7 pb in the AdOaCD70 group. AdOaCD70 administration could therefore promote CD8+ T cell effector differentiation and long-term activity. In this work we characterized the in vivo adjuvant potential on the humoral and cellular immune response of OaOX40L and OaCD70 delivered by non-replicative adenovirus vectors using the model antigen OVA. We present data highlighting the potency of these molecules as veterinary vaccine adjuvant.

show abstract

“…This high immunogenicity, combined with the lack of pathogenicity and capacity for accommodating large amounts of foreign genetic material [ 23 ], has resulted in considering BoHV-4 as a promising vaccine vector. To date, BoHV-4 vectors have been used to deliver a variety of heterologous antigens from different pathogens in several animal models [ 21 , 23 , 25 , 26 , 27 , 28 , 29 ].…”

Section: Introductionmentioning

confidence: 99%

Bovine Herpesvirus-4 Based Vaccine Provides Protective Immunity against Streptococcus suis Disease in a Rabbit Model

et al. 2023

View full text Add to dashboard Cite

Streptococcus suis (S. suis) is a bacterial pathogen of pigs that has a major animal health and economic impact on the pig industry. Bovine herpesvirus-4 (BoHV-4) is a new virus-based vaccine vector that has been used for the immunogenic delivery of antigens from a variety of pathogens. In the present study, two recombinant BoHV-4-based vectors were evaluated for their ability to induce immunity and protection against S. suis in a rabbit model. The GMD protein is a fusion protein consisting of multiple dominant B-cell epitopes ((B-cell dominant epitopes of GAPDH, MRP, and DLDH antigens) (BoHV-4/GMD)) and the second suilysin (SLY) (BoHV-4/SLY) from S. suis serotype 2 (SS2). Both GMD and SLY delivered by the BoHV-4 vectors were recognized by sera from SS2-infected rabbits. The vaccination of rabbits with the BoHV-4 vectors induced antibodies against SS2, as well as against additional S. suis serotypes, SS7 and SS9. However, sera from BoHV-4/GMD-vaccinated animals promoted a significant level of phagocytic activity by pulmonary alveolar macrophages (PAMs) against SS2, SS7, and SS9. In contrast, sera from rabbits immunized with BoHV-4/SLY induced PAM phagocytic activity against only SS2. In addition, BoHV-4 vaccines differed in the associated level of protection against lethal SS2 challenge, which ranged from high (71.4%) to low (12.5%) for BoHV-4/GMD and BoHV-4/SLY, respectively. These data suggest BoHV-4/GMD as a promising vaccine candidate against S. suis disease.

show abstract

Immunization With Bovine Herpesvirus-4-Based Vector Delivering PPRV-H Protein Protects Sheep From PPRV Challenge

Cited by 9 publications

References 44 publications

Characterization and phylogenetic analysis of bovine gammaherpesvirus 4 isolated in China, 2022

Characterization and phylogenetic analysis of bovine gammaherpesvirus 4 isolated in China, 2022

Adenoviral delivery of soluble ovine OX40L or CD70 costimulatory molecules improves adaptive immune responses to a model antigen in sheep

Bovine Herpesvirus-4 Based Vaccine Provides Protective Immunity against Streptococcus suis Disease in a Rabbit Model

Contact Info

Product

Resources

About